$1.63
2.20% today
Nasdaq, Feb 28, 05:21 pm CET
ISIN
US8776191061
Symbol
TSHA
Sector
Industry

Taysha Gene Therapies Inc Stock price

$1.59
+0.06 3.92% 1M
-0.55 25.70% 6M
-0.14 8.09% YTD
-0.86 35.10% 1Y
-4.78 75.04% 3Y
-18.41 92.05% 5Y
-18.41 92.05% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-0.03 1.85%
ISIN
US8776191061
Symbol
TSHA
Sector
Industry

Key metrics

Market capitalization $325.86m
Enterprise Value $250.32m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 30.05
P/S ratio (TTM) P/S ratio 39.12
P/B ratio (TTM) P/B ratio 4.56
Revenue growth (TTM) Revenue growth -46.07%
Revenue (TTM) Revenue $8.33m
EBIT (operating result TTM) EBIT $-86.62m
Free Cash Flow (TTM) Free Cash Flow $-81.60m
Cash position $139.49m
EPS (TTM) EPS $-0.38
P/E forward negative
P/S forward 56.19
EV/Sales forward 43.17
Short interest 15.51%
Show more

Is Taysha Gene Therapies Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Taysha Gene Therapies Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Taysha Gene Therapies Inc forecast:

11x Buy
100%

Analyst Opinions

11 Analysts have issued a Taysha Gene Therapies Inc forecast:

Buy
100%

Financial data from Taysha Gene Therapies Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
8.33 8.33
46% 46%
100%
- Direct Costs 1.23 1.23
39% 39%
15%
7.10 7.10
47% 47%
85%
- Selling and Administrative Expenses 27 27
2% 2%
318%
- Research and Development Expense 66 66
16% 16%
792%
-85 -85
23% 23%
-1,025%
- Depreciation and Amortization 1.23 1.23
39% 39%
15%
EBIT (Operating Income) EBIT -87 -87
21% 21%
-1,040%
Net Profit -89 -89
20% 20%
-1,072%

In millions USD.

Don't miss a Thing! We will send you all news about Taysha Gene Therapies Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Taysha Gene Therapies Inc Stock News

Neutral
Seeking Alpha
2 days ago
Taysha Gene Therapies, Inc. (NASDAQ:TSHA ) Q4 2024 Earnings Conference Call February 26, 2025 8:30 AM ET Company Participants Hayleigh Collins - Director & Head of Investor Relations Sean Nolan - Chief Executive Officer Sukumar Nagendran - President & Head of R&D Kamran Alam - Chief Financial Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald Salveen Richter - Goldman Sachs...
Neutral
GlobeNewsWire
2 days ago
High dose and low dose of TSHA-102 continue to be generally well tolerated with no treatment-related SAEs or DLTs in all pediatric, adolescent and adult patients treated (high dose, n=6; low dose, n=4) across both REVEAL trials as of February 2025 data cutoff Completed dosing of the 10 patients in Part A of both REVEAL trials; maturing dataset continues to support advancement toward pivotal Par...
Neutral
GlobeNewsWire
9 days ago
DALLAS, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the full-year ended December 31, 2024, and host a corporate update confe...
More Taysha Gene Therapies Inc News

Company Profile

Taysha Gene Therapies, Inc. engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. It also develops multiple gene therapy platforms which include AAV9 Discovery, Novel Capsid, and AAV Redosing. The company was founded by Steven Gray, Berge Minassian, and R. A. Session II on September 20, 2019 and is headquartered in Dallas, TX.

Head office United States
CEO Sean Nolan
Employees 73
Founded 2019
Website www.tayshagtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today